French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals
MAISON-ALFORT, France--(BUSINESS WIRE)--Apr 16, 2019--Thanks to this strategic partnership, CellVaxcan now respond to the strong demandfor optimal selection of models that represent the human disease best and is ableto offer preclinical studies in large nonrodent species as well as diversified preclinical models or clinical trials.
Large animal models are essential for the development of novel therapeutics for Cancer and Osteoarthritis (OA) fields, the two research specialties of CellVax. Through this partnership, the company has achieved a significant progress in its capacity to provide wide range of animal models for these diseases.
From now on, CellVax offers to fully realize high value-added projects in China and France / Europe, including product registrations in China for European clients, or a better understanding of European markets for Chinese clients.
Quicker funding to support the growth and to finance quality and R&D resources, innovation driver for CellVax
Since February 2019, CellVax has made a strong commitment to enhance the quality of its preclinical studies. Currently, one large GLP toxicology and Bio-distribution study is ongoing at CellVax.
By the end of 2019, CellVax will be able to perform a full range of GLP-compliant preclinical studies in large and small animals for the development of drugs, vaccines and medical devices.
Furthermore, CellVax is fully invested in numerous large-scale European collaborative research programs such as Eureka, FP-7, and Horizon 2020, as well as in the search for new ways of private / public financing in order to continually enhance its R&D capability and to increase its visibility worldwide.
About CellVax –
Founded in 2001, Cellvax is a preclinical Contract Research Organization (CRO) which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis fields. In addition to preclinical studies, CellVax provides high quality consulting services in order to optimize the discovery process of candidate compounds.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005023/en/
Dr. Mingxing WEI, CEO
+33 (0) 671434751 (France); +86 182 271 08395 (China)
+33 1 39 97 61 22
KEYWORD: EUROPE ASIA PACIFIC CHINA FRANCE
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE
Copyright Business Wire 2019.
PUB: 04/16/2019 08:00 AM/DISC: 04/16/2019 08:00 AM